{
  "id": 16091,
  "label": "acute myeloid leukemia and myelodysplastic syndromes related to topoisomerase type 2 inhibitor",
  "model": {
    "label": "Mondo Disease Ontology (MONDO)",
    "source": 0
  },
  "type_id": 0,
  "reference_id": "MONDO:0015165",
  "properties": {
    "xrefs": [
      "GARD:0019836",
      "MEDGEN:1639654",
      "Orphanet:102381",
      "UMLS:C4707659",
      "icd11.foundation:88207494"
    ],
    "synonyms": [
      "AML and myelodysplastic syndromes related to topoisomerase type 2 inhibitor"
    ],
    "categories": [
      {
        "ref": "MONDO:0002081",
        "name": "musculoskeletal system disorder"
      },
      {
        "ref": "MONDO:0003900",
        "name": "connective tissue disorder"
      },
      {
        "ref": "MONDO:0005046",
        "name": "immune system disorder"
      },
      {
        "ref": "MONDO:0005570",
        "name": "hematologic disorder"
      }
    ],
    "definition": "Acute myeloid leukemia and myelodysplastic syndromes related to topoisomerase type 2 inhibitor represent a subgroup of therapy-related myeloid neoplasms (t-MN), associated with treatment of an unrelated neoplastic disease with cytotoxic agents, like etoposid, doxorubicin, daunorubicin and others. The neoplastic cells often show rearrangements involving the mixed lineage leukemia gene at 11q23. This subgroup of t-MN is typically associated with overt leukemia, without preceding myelodysplastic syndrome, developing 2-3 years after exposure, presenting with non-specific symptoms related to ineffective hematopoesis (fatigue, bleeding and bruising, recurrent infections, bone pain) and/or extramedullary site involvement."
  },
  "isLeaf": true,
  "isRoot": false,
  "child_count": 0,
  "parents": [
    {
      "id": 19283,
      "label": "therapy related acute myeloid leukemia and myelodysplastic syndrome",
      "isLeaf": false,
      "isRoot": false,
      "parents": [
        18806
      ],
      "type_id": 0,
      "properties": {
        "xrefs": [
          "GARD:0012762",
          "MEDGEN:220954",
          "NCIT:C25765",
          "Orphanet:86846",
          "SCTID:721306009",
          "UMLS:C1292776",
          "icd11.foundation:1581599493"
        ],
        "synonyms": [
          "Secondary AGL",
          "Secondary Acute granulocytic Leukaemia",
          "Secondary Acute granulocytic Leukemia",
          "Secondary Acute myeloblastic Leukaemia",
          "Secondary Acute myeloblastic Leukemia",
          "Secondary Acute myelocytic Leukaemia",
          "Secondary Acute myelocytic Leukemia",
          "Secondary Acute myelogenous Leukaemia",
          "Secondary Acute myelogenous Leukemia",
          "Secondary Acute myeloid Leukaemia (AML)",
          "Secondary Acute myeloid Leukemia (AML)",
          "secondary AML",
          "secondary acute myeloid leukaemia",
          "secondary acute myeloid leukemia",
          "therapy-related AML and myelodysplastic syndrome"
        ],
        "categories": [
          {
            "ref": "MONDO:0002081",
            "name": "musculoskeletal system disorder"
          },
          {
            "ref": "MONDO:0003900",
            "name": "connective tissue disorder"
          },
          {
            "ref": "MONDO:0005046",
            "name": "immune system disorder"
          },
          {
            "ref": "MONDO:0005570",
            "name": "hematologic disorder"
          }
        ],
        "definition": "An acute myeloid leukemia secondary to a myelodysplastic syndrome or therapy-related. (WHO, 2001)"
      },
      "child_count": 3,
      "reference_id": "MONDO:0019457"
    }
  ],
  "children": [],
  "roots": [
    {
      "id": 19283,
      "label": "therapy related acute myeloid leukemia and myelodysplastic syndrome"
    }
  ]
}